Loading...
Loading...
Osiris Therapeutics
OSIR announced today the successful conclusion of a patent
challenge in Australia by an opponent whose identity under Australian
law was not disclosed. The patent at issue covers the administration of
mesenchymal stem cells (MSCs), including Prochymal® (remestemcel-L),
for the treatment of inflammatory conditions involving the
gastrointestinal tract, including Crohn's disease and ulcerative colitis.
As acknowledged in the Australian Official Journal of Patents
Supplement, all claims to the patent will be maintained in full. The
claims specifically include the use of allogeneic MSCs, an attribute
central to making an off-the-shelf MSC product possible.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in